Keryx Biopharmaceuticals (NASDAQ:KERX)’S Auryxia Finds Favor In The Eyes Of Nation’s Largest Medicare Part D Plan Sponsor


One of world’s giant biopharmaceutical companies, Keryx Biopharmaceuticals (NASDAQ:KERX) has gone ahead to make one of the most exciting announcements in its history. It has made it known that the nation’s largest Medicare Part D plan sponsor has gone ahead to include Auryxia® (ferric citrate) to its Medicare Part D plan formularies and that has to commence right away.

The announcement did not only excite the company but also its many investors who believe that the company is headed to the right direction and will soon be generating high revenues. One of the company’s top officials has stated that there is hope for patients around the globe looking at the plans the company has been laying down in the recent past to see to it that the company moves a notch higher in terms of providing better medical solutions to patients around the globe.

This high end company has been operating for many years, basing itself with the much needed experience to make it in the business world. According to one of the top executives working with Keryx Biopharmaceuticals, the company remains committed to doing all within its means towards delivering innovative medicines to people with renal disease.

In the U.S, Auryxia has won its place as a trusted and effective remedy for controlling serum phosphorus levels in persons struggling with chronic kidney disease (CKD) on dialysis. The president and chief executive officer of Keryx Biopharmaceuticals, Greg Madison, while speaking on behalf of the company expressed that the company was actually excited following the thoughts of one of the top insurance providers regarding Auryxia. The insurance provider thought of Auryxia as top medication which was actually great value to patients around the globe.

He also went ahead to state that the new formularies had the capacity to help the company make tremendous steps forward towards giving a major lift to Auryxia in dealing carrying out dialysis. The company is hopeful that it will succeed on its quest to give a great access to persons struggling with iron deficiency anemia (IDA).

The market dynamics which are in a major way being triggered with technological advancements are resulting to wild competition among top providers. This company I competing quite well and even hopes for a brighter future.